Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-031635
Filing Date
2024-08-13
Accepted
2024-08-13 16:30:50
Documents
55
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 648129
2 ex31-1.htm EX-31.1 18332
3 ex31-2.htm EX-31.2 18923
4 ex32-1.htm EX-32.1 10522
  Complete submission text file 0001493152-24-031635.txt   3417691

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE impb-20240630.xsd EX-101.SCH 25634
6 XBRL CALCULATION FILE impb-20240630_cal.xml EX-101.CAL 40792
7 XBRL DEFINITION FILE impb-20240630_def.xml EX-101.DEF 90703
8 XBRL LABEL FILE impb-20240630_lab.xml EX-101.LAB 223258
9 XBRL PRESENTATION FILE impb-20240630_pre.xml EX-101.PRE 178683
57 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 382133
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42212 | Film No.: 241202176
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)